Outlook for 2022: A New Benchmark in the Biopharmaceutical Industry with Equal Emphasis on Clinical Value and Innovation Quality

China's biopharmaceutical industry stimulated its innovation vitality in the exploration of high-quality and sustainable development in an environment of uncertainty in 2021.Taking the unmet clinical needs as the starting point, biopharmaceutical companies should find their right position in the innovation transformation in the industry as a whole with more attention to the value of medicines in 2022.Through a series of brainstorming roundtables, Shanghai Center for Innovation Drug Discovery and Development (SCIDDD) has proposed the outlook of 2022 for China's biopharmaceutical industry, highlighting the importance for biopharmaceutical enterprises to accelerate the reoriented clinical value and improve innovation quality.